BACKGROUND: Malnutrition is common at diagnosis and during treatment for sarcoma patients. Poor nutritional status is associated with increased risk of complications, particularly infections. We investigated the role of body mass index (BMI) on the incidence of surgical wound complications in patients with localized osteosarcoma treated on the Children's Oncology Group (COG) legacy trial, INT-0133. PROCEDURE: Patients considered in this report had localized osteosarcoma, enrolled on COG trial INT-0133, remained on protocol therapy to have definitive surgery 6-16 weeks after study entry, and had adequate height, weight, and surgical complication data for analysis. By protocol design, definitive surgical resection was planned for 10 weeks after induction chemotherapy. Wound complications within 30 days after definitive surgery were considered post-operative. BMI was calculated at the start of neoadjuvant chemotherapy and expressed as age- and gender-adjusted percentile. The incidence of wound complications was evaluated by logistic regression or Fisher's exact test. RESULTS: A total of 498 patients met criteria for analysis. Low BMI (≤10th percentile) was seen in 73 (14.7%), middle BMI (11th-94th percentile) in 382 (76.7%), and high BMI (≥95th percentile) in 43 (8.6%) patients. Wound infection or slough was seen in low BMI patients (OR = 2.0, P = 0.07) although the results did not reach statistical significance. Arterial thrombosis was more common in high BMI patients (OR = 9.4, P = 0.03). CONCLUSIONS: Abnormal BMI at the start of treatment for localized osteosarcoma is associated with increased risk of post-operative wound complications such as arterial thrombosis. Future studies should evaluate whether maintenance of age-appropriate BMI reduces the risk of surgical complications.
BACKGROUND: Malnutrition is common at diagnosis and during treatment for sarcomapatients. Poor nutritional status is associated with increased risk of complications, particularly infections. We investigated the role of body mass index (BMI) on the incidence of surgical wound complications in patients with localized osteosarcoma treated on the Children's Oncology Group (COG) legacy trial, INT-0133. PROCEDURE: Patients considered in this report had localized osteosarcoma, enrolled on COG trial INT-0133, remained on protocol therapy to have definitive surgery 6-16 weeks after study entry, and had adequate height, weight, and surgical complication data for analysis. By protocol design, definitive surgical resection was planned for 10 weeks after induction chemotherapy. Wound complications within 30 days after definitive surgery were considered post-operative. BMI was calculated at the start of neoadjuvant chemotherapy and expressed as age- and gender-adjusted percentile. The incidence of wound complications was evaluated by logistic regression or Fisher's exact test. RESULTS: A total of 498 patients met criteria for analysis. Low BMI (≤10th percentile) was seen in 73 (14.7%), middle BMI (11th-94th percentile) in 382 (76.7%), and high BMI (≥95th percentile) in 43 (8.6%) patients. Wound infection or slough was seen in low BMI patients (OR = 2.0, P = 0.07) although the results did not reach statistical significance. Arterial thrombosis was more common in high BMI patients (OR = 9.4, P = 0.03). CONCLUSIONS: Abnormal BMI at the start of treatment for localized osteosarcoma is associated with increased risk of post-operative wound complications such as arterial thrombosis. Future studies should evaluate whether maintenance of age-appropriate BMI reduces the risk of surgical complications.
Authors: Zuguo Mei; Laurence M Grummer-Strawn; Angelo Pietrobelli; Ailsa Goulding; Michael I Goran; William H Dietz Journal: Am J Clin Nutr Date: 2002-06 Impact factor: 7.045
Authors: Paul A Meyers; Cindy L Schwartz; Mark Krailo; Eugenie S Kleinerman; Donna Betcher; Mark L Bernstein; Ernest Conrad; William Ferguson; Mark Gebhardt; Allen M Goorin; Michael B Harris; John Healey; Andrew Huvos; Michael Link; Joseph Montebello; Helen Nadel; Michael Nieder; Judith Sato; Gene Siegal; Michael Weiner; Robert Wells; Lester Wold; Richard Womer; Holcombe Grier Journal: J Clin Oncol Date: 2005-03-20 Impact factor: 44.544
Authors: Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson Journal: Vital Health Stat 11 Date: 2002-05
Authors: Paul A Meyers; Cindy L Schwartz; Mark D Krailo; John H Healey; Mark L Bernstein; Donna Betcher; William S Ferguson; Mark C Gebhardt; Allen M Goorin; Michael Harris; Eugenie Kleinerman; Michael P Link; Helen Nadel; Michael Nieder; Gene P Siegal; Michael A Weiner; Robert J Wells; Richard B Womer; Holcombe E Grier Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544
Authors: Paul C Rogers; Steven J Melnick; Elena J Ladas; Jacqueline Halton; Jacques Baillargeon; Nancy Sacks Journal: Pediatr Blood Cancer Date: 2008-02 Impact factor: 3.167
Authors: Megan E Burke; Elizabeth R Lyden; Jane L Meza; Elena J Ladas; Roshni Dasgupta; Ellen A Wiegner; Carola A S Arndt Journal: Pediatr Blood Cancer Date: 2013-01-17 Impact factor: 3.167
Authors: Meena Bedi; Cecilia G Ethun; John Charlson; Thuy B Tran; George Poultsides; Valerie Grignol; J Harrison Howard; Jennifer Tseng; Kevin K Roggin; Konstantinos Chouliaras; Konstantinos Votanopoulos; Darren Cullinan; Ryan C Fields; Kenneth Cardona; David M King Journal: Clin Orthop Relat Res Date: 2020-03 Impact factor: 4.755
Authors: Annabel G Small; Le M Thwe; Jennifer A Byrne; Loretta Lau; Albert Chan; Maria E Craig; Chris T Cowell; Sarah P Garnett Journal: Medicine (Baltimore) Date: 2015-04 Impact factor: 1.889
Authors: Priscila Dos Santos Maia Lemos; Fernanda Luisa Ceragioli de Oliveira; Eliana Maria Monteiro Caran Journal: Rev Bras Hematol Hemoter Date: 2014-07-09